Matairesinol ameliorates experimental autoimmune uveitis by suppression of IRBP-specific Th17 cells

J Neuroimmunol. 2020 Aug 15:345:577286. doi: 10.1016/j.jneuroim.2020.577286. Epub 2020 Jun 6.

Abstract

We investigated the effects of matairesinol (MAT) in the experimental autoimmune uveitis (EAU), a classical animal model of uveitis. We found that treatment with MAT could alleviate intraocular inflammation of EAU. Notably, Th17 cells in eyes of EAU mice could be predominantly restrained by MAT. Furthermore, MAT could inhibit Th17 differentiation in vitro. In addition, MAT inhibited the signaling of MAPK and ROR-γt, a pivotal transcription factor for Th17 cell differentiation in vitro and in vivo. Taken together, these results suggested that MAT had immune-suppressive effects on autoimmune inflammation through Th17 cells.

Keywords: EAU; MAPK; Matairesinol; ROR-γt; Th17 cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Autoimmune Diseases / drug therapy*
  • Autoimmune Diseases / immunology
  • Autoimmune Diseases / metabolism
  • Eye Proteins / antagonists & inhibitors*
  • Eye Proteins / immunology
  • Eye Proteins / metabolism
  • Female
  • Freund's Adjuvant / toxicity
  • Furans / pharmacology
  • Furans / therapeutic use*
  • Lignans / pharmacology
  • Lignans / therapeutic use*
  • Mice
  • Mice, Inbred C57BL
  • Retinol-Binding Proteins / antagonists & inhibitors*
  • Retinol-Binding Proteins / immunology
  • Retinol-Binding Proteins / metabolism
  • Th17 Cells / drug effects*
  • Th17 Cells / immunology
  • Th17 Cells / metabolism
  • Uveitis / drug therapy*
  • Uveitis / immunology
  • Uveitis / metabolism

Substances

  • Eye Proteins
  • Furans
  • Lignans
  • Retinol-Binding Proteins
  • interstitial retinol-binding protein
  • matairesinol
  • Freund's Adjuvant